Genetic factors in the pathogenesis of CPPD crystal deposition disease

Current Rheumatology Reports

Volumn 9, Issue 3, 2007, Pages 231-236

  Couto, Ana Rita ^c   Brown, Matthew A ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM PYROPHOSPHATE; ESTERASE; HYDROXYAPATITE; NUCLEOTIDE PYROPHOSPHATE PHOSPHODIESTERASE; PYROPHOSPHATE; UNCLASSIFIED DRUG;

BIOLOGICAL MODEL; CHONDROCALCINOSIS; CRYSTAL STRUCTURE; CRYSTALLIZATION; DNA POLYMORPHISM; EXTRACELLULAR FLUID; GENE ACTIVITY; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; HEREDITY; HUMAN; HYPEROSTOSIS; MINERAL BALANCE; MINERALIZATION; MONOGENIC DISORDER; NONHUMAN; PROMOTER REGION; REVIEW;

ANIMALS; CHONDROCALCINOSIS; DISEASE MODELS, ANIMAL; HUMANS; HYPEROSTOSIS, DIFFUSE IDIOPATHIC SKELETAL; HYPOPHOSPHATASIA; MICE; PHOSPHATE TRANSPORT PROTEINS; PHOSPHORIC DIESTER HYDROLASES; POLYMORPHISM, GENETIC; PYROPHOSPHATASES;

EID: 34250768831     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0037-7     Document Type: Review

References (50)

1. Fleisch H, Bisaz S: Mechanism of calcification: inhibitory role of pyrophosphate. Nature 1962, 195:911.
2. Terkeltaub RA: Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 2001, 281:0-01.
3. Murshed M, Harmey D, Millan JL, et al.: Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005, 19:1093-1104. Fascinating study demonstrating that Pi rather than Ca is the key regulator of mineralization, and that the basic requirements determining tissue specificity are the presence of alkaline phosphatase and fibrillary collagen.
4. Zitnan D, Sitaj S: Chondrocalcinosis articularis. Ann Rheum Dis 1963, 22:142-152.
5. Reginato A, Valenzuela F, Martinez V, et al.: Polyarticular and familial chondrocalcinosis. Arthritis Rheum 1970, 13:197-213.
6. Van der Korst JK, Gerards J, Driessens FM: A hereditary type of idiopathic articular chondrocalcinosis. Survey of a pedigree. Am J Med Genet 1974, 56:307-314.
7. Reginato A: Articular chondrocalcinosis in the Chiloe Islanders. Arthritis Rheum 1976, 19(Suppl 3):395-404.
8. Gaudreau A, Camerlain M, Pibarot ML, et al.: Familial articular chondrocalcinosis in Quebec. Arthritis Rheum 1981, 24:611-615.
9. Bjelle A, Edvinson U, Hagstam A: Pyrophosphate arthropathy in two Swedish families. Arthritis Rheum 1982, 25:66-74.
10. Rodriguez-Valverde V, Zuniga M, Casanueva B, et al.: Hereditary articular chondrocalcinosis. Am J Med 1988, 84:101-106.
11. Balsa A, Martin-Mola E, Gonzalez T, et al.: Familial articular chondrocalcinosis in Spain. Ann Rheum Dis 1990, 49:531-535.
12. Eshel G, Gulik A, Halperin N, et al.: Hereditary chondrocalcinosis in an Ashkenazi Jewish family. Ann Rheum Dis 1990, 49:528-530.
13. Doherty M, Hamilton E, Henderson J, et al.: Familial chondrocalcinosis due to calcium pyrophosphate dihydrate crystal deposition in English Families. Br J Rheum 1991, 30:10-15.
14. Hamza M, Meddeb N, Bardin T: Hereditary chondrocalcinosis in a Tunisian family. Clin Exp Rheum 1992, 10:43-49.
15. Pons-Estel BA, Gimenez C, Sacnun M, et al.: Familial osteoarthritis and Milwaukee shoulder associated with calcium pyrophosphate and apatite crystal deposition. J Rheumatol 1999, 27:471-480.
16. Bruges-Armas J, Couto AR, Timms A, et al.: Ectopic calcification among families in the Azores: clinical and radiological manifestations in families with diffuse idiopathic skeletal hyperostosis and chondrocalcinosis. Arthritis Rheum 2006, 54:1340-1349. Report of a novel group of families with coinheritance with a monogenic pattern of DISH and CC, suggesting that the conditions have shared genetic features.
17. Rodriguez-Valverde V, Tinture T, Zuniga M, et al.: Familial chondrocalcinosis. Prevalence in Northern Spain and clinical features in five pedigrees. Arthritis Rheum 1980, 23:471-478.
18. Fernandez-Dapica MP, Gomez-Reino JJ: Familial chondrocalcinosis in the Spanish population. J Rheumatol 1986, 13:631-633.
19. Reginato A, Orces C, Ronda, et al.: Calcium pyrophosphate deposition disease in a kindred of Spanish-Mapuche ancestry. Arthritis Rheum 1995, 38:S246.
20. Zhang W, Neame R, Doherty S, Doherty M: Relative risk of knee chondrocalcinosis in siblings of index cases with pyrophosphate arthropathy. Ann Rheum Dis 2004, 63:969-973.
21. Baldwin CT, Farrer LA, Adair R, et al.: Linkage of early-onset osteoarthritis and chondrocalcinosis to human chromosome 8q. Am J Hum Genet 1995, 56:692-697.
22. Hughes AE, McGibbon D, Woodward E, et al.: Localisation of a gene for chondrocalcinosis to chromosome 5p. Hum Mol Genet 1995, 4:1225-1228.
23. Andrew LJ, Brancolini V, Serrano de la Pena L, et al.: Refinement of the chromosome 5p locus for familial calcium pyrophosphate dihydrate deposition disease. Am J Hum Genet 1999, 64:136-145.
24. Ho AM, Johnson MD, Kingsley DM: Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000, 289:265-289.
25. Timms AE, Zhang Y, Russel RG, Brown MA: Genetic studies of disorders of calcium crystal deposition. Rheumatol 2002, 41:725-729.
26. Williams CJ, Zhang Y, Timms A, et al.: Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 2002, 71:985-991.
27. Pendleton A, Johnson MD, Hughes AE, et al.: Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002, 71:933-940.
28. Williams CJ, Pendleton A, Bonavita G, et al.: Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 2003, 48:2627-2631.
29. Zhang Y, Johnson K, Russell RG, et al.: Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5′-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum 2005, 52:1110-1117. Demonstrates a role for a novel polymorphism of ANKH in severe "sporadic" CC. Mutations associated with CPPD CC shown to be "gain of expression," though functional consequences differed between different mutations.
30. Reichenberger E, Tiziani V, Watanabe S, et al.: Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet 2001, 68:1321-1326.
31. Nurnberg P, Thiele H, Chandler D, et al.: Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nature Genet 2001, 28:37-41.
32. Gurley KA, Reimer RJ, Kingsley DM: Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet 2006, 79:1017-1029. Superb series of experiments in transgenic mice and in vitro systems indicating that hydroxyapatite-associated ANKH mutations cause reduced export of PPi from cells, but that CPPD-associated mutations did not significantly effect PPi transport.
33. Zaka R, Stokes D, Dion AS, et al.: P5L mutation in Ank results in an increase in extracellular inorganic pyrophosphate during proliferation and nonmineralizing hypertrophy in stably transduced ATDC5 cells. Arthritis Res Ther 2006, 8:R164. Stable transfectants of the CPPD-associated P5L Ank mutant demonstrated gain-of-function with respect to increasing extracellular PPi levels, but this effect was modified by varying levels of alkaline phosphatase expression during differentiation.
34. Ryan LM, Kurup I, Cheung HS: Stimulation of cartilage inorganic pyrophosphate elaboration by ascorbate. Matrix 1991, 11:276-281.
35. McKee S, Pendleton A, Dixey J, et al: Autosomal dominant early childhood seizures associated with chondrocalcinosis and a mutation in the ANKH gene. Epilepsia 2004, 45:1258-1260. Further characterisation of British family with seizures and CC, carrying -11C>T mutation in ANKH. Raises the hypothesis that ANKH mutations may play a role in other forms of epilepsy.
36. Malkin I, Ermakov S, Kobyliansky E, Livshits G: Strong association between polymorphisms in ANKH locus and skeletal size traits. Hum Genet 2006, 120:42-51. Association reported between vertebral column length and biacromial breadth (adjusted for height) with ANKH variation. Group has previously reported in a different population association with ANKH variants and hand bone size. Warrants follow-up in a substantial cohort.
37. Vistoropsky Y, Malkin I, Kobyliansky E, Livshits G: Osteoprotegerin plasma levels are strongly associated with polymorphisms in human homologue of the mouse progressive ankylosis (ANKH) gene. Ann Hum Genet 2006, Epub ahead of print. Strong association reported between osteoprotegerin levels and ANKH variation. Small sample size and no confirmation dataset.
38. Tsui FW, Tsui HW, Cheng EY, et al.: Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 2003, 48:791-797.
39. Timms AE, Zhang Y, Bradbury L, et al.: Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum 2003, 48:2898-2902.
40. Nakamura I, Ikegawa S, Okawa A, et al.: Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet 1999, 104:492-497.
41. Rutsch F, Ruf N, Vaingankar S, et al.: Mutations in ENPP1 are associated with "idiopathic" infantile arterial calcification. Nature Genet 2003, 34:379-381.
42. Okawa A, Nakamura I, Goto S, et al.: Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998, 19:271-273.
43. Rutsch F, Ruf N, Vaingankar S, et al.: Mutations in ENPP1 are associated with "idiopathic" infantile arterial calcification. Nat Genet 2003, 34:379-381.
44. Zhang Y, Brown MA, Peach C, et al.: Investigation of the role of ENPP1 and TNAP genes in chondrocalcinosis. Rheumatology (Oxford) 2006, Epub ahead of print. No major effect of polymorphisms of ENPP1 and TNAP observed on CPPD CC. Small to moderate effects were not excluded.
45. Mornet E, Taillandier A, Peyramaure S, et al.: Identification of fifteen novel mutations in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in European patients with severe hypophosphatasia. Eur J Hum Genet 1998, 6:308-314.
46. Hessle L, Johnson KA, Anderson HC, et al.: Tissue-non-specific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. PNAS 2002, 99:9445-9449.
47. Mandel GS, Halverson PB, Mandel NS: Calcium pyrophosphate crystal deposition: the effect of soluble iron in a kinetic study using a gelatin matrix model. Scanning Microsc 1988, 2:1177-1188.
48. Cheng PT, Pritzker KP: Ferrous [Fe++] but non ferric [Fe] ions inhibit de novo formation of calcium pyrophosphate dihydrate crystals: possible relationships to chondrocalcinosis and hemochromatosis. J Rheumatol 1988, 15:321-324.
49. McCarty DJ, Palmer DW, Garancis JC: Clearance of calcium pyrophosphate dihydrate crystals in vivo. III. Effects of synovial hemosiderosis. Arthritis Rheum 1981, 24:706-710.
50. Urakawa I, Yamazaki Y, Shimada T, et al.: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774. Ground-breaking paper demonstrating that Klotho interacts with FGF-23, leading to loss of FGF-23 function. Klotho mice develop premature ageing, osteoporosis, and atherosclerosis. This paper will launch a thousand studies.